Targeting N-RAS mutated tumours
30 Oct 2015
Targeting N-RAS mutated tumours
HVEM expression in melanoma metastasis: prognosis correlation
Vemurafenib in patients with BRAF600 mutation–positive metastatic melanoma
Preventing cancer in the EU through legislation, education and taxation
Lessening the global financial burden of cancer
Research reproducibility and scientific ecosystems
Economics of radiation therapy
Can early stage NSCLC be treated with stereotactic radiation therapy?
Stereotactic radiation therapy for oligmetastases
Can SBRT be of use for early, operable non-small cell lung cancer?
Investigating genetic vulnerabilities to radiation therapy
Raising the bar on radiation oncology excellence